Over 2021, the hard work and dedication of the entire Celyad Oncology team has helped us to continue to make steady progress advancing our mission to develop next-generation allogeneic CAR T candidates that offer new therapeutic options to cancer patients with poor prognosis. Our development pipeline has continued to transition to an allogeneic strategy centered around
i) our single-step engineering, All-in-One vector approach and
ii) our proprietary non-gene edited technologies including short hairpin RNA (shRNA) and T cell receptor Inhibitory Molecule (TIM).
Throughout the past twelve months, we’ve announced encouraging clinical data from our programs at major scientific conferences and further built our position as a leader in the field of allogeneic CAR T cell therapies.
